Identifying vulnerable populations among breast cancer survivors.

2018 ◽  
Vol 36 (7_suppl) ◽  
pp. 176-176
Author(s):  
Kit Yu Lu ◽  
Theresa M. Lee ◽  
Megan Lanigan ◽  
Beth Rudge ◽  
Yijin Wert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Retrospective Analysis ◽  
Vulnerable Populations ◽  
Breast Cancer Survivors ◽  
Quality Care ◽  
Hot Flashes ◽  
Post Treatment ◽  
Fisher Exact Test ◽  
Term Survival

176 Background: Long term survival is common after breast cancer treatment with 5-year survival rate reaching almost 90%. Many breast cancer survivors (BCS) face varying degrees of quality of life (QOL) issues depending on their age of diagnosis, severity of their disease, and treatment course. This is a retrospective analysis to describe demographics, QOL concerns, and to identify vulnerable populations among the BCS. Methods: This is a retrospective analysis of BCS seen at our Breast Cancer Survivorship Program from Oct 2016 to Oct 2017. Patients were given a comprehensive survey to assess self-reported symptoms and concerns following their treatment. Chi-square test was used to analyze group differences. The Fisher exact test was employed when any of the expected frequencies was five or less. Results: 252 patients (age 26-93; median 60) were seen. Characteristics are listed in the Table. Most common self-reported concerns affecting BCS were: fatigue (40%), insomnia (38%), hot flashes (29%), night sweats (26%), pain (26%), trouble concentrating (26%), and neuropathy (25%). Majority(87%) reported having a happy outlook and felt that they have a sense of purpose (85%), but about 12% of BCS felt isolated at least 50% of their time. Young cancer survivors (age ≤45) (p<0.0001), higher stage BCS (Stage 2-3) (p=0.0023), and those who had chemotherapy either alone or as part of their multi-modality treatment (p=0.0061) were significantly more likely to worry about their cancer post treatment. The same populations were significantly less likely to return back to at least 50% of their pre-treatment baseline (young cancer survivors p=0.0049; higher stage p=0.0011; chemo+/-other treatments p=0.0012). Conclusions: Majority of BCS report a happy and optimistic outlook post treatment, but some may experience significant QOL issues. Identifying common concerns after treatments and vulnerable populations are especially important to deliver quality care and to optimize interventions. [Table: see text]

Hot Flashes in Breast Cancer Survivors

2003 ◽  
Vol 9 (5) ◽  
pp. 431-438 ◽  
Author(s):  
Daanish Hoda ◽  
Domingo G. Perez ◽  
Charles L. Loprinzi
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Hot Flashes

Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations

2013 ◽  
Vol 21 (5) ◽  
pp. 1461-1474 ◽  
Author(s):  
Sylvain L’Espérance ◽  
◽  
Suzanne Frenette ◽  
Anne Dionne ◽  
Jean-Yves Dionne
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Hot Flashes ◽  
Hormonal Treatment

scholarly journals Effect of Tai Chi Chuan practice on immune system and pro-metastasis markers in early post-treatment breast cancer survivors

2021 ◽  
Vol 12 (1) ◽  
pp. 013-019
Author(s):  
Mary NB Cheung ◽  
Wings Tjing Yung Loo
Keyword(s):  
Breast Cancer ◽  
Immune System ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Tai Chi ◽  
Complete Blood Count ◽  
Post Treatment ◽  
Control Group ◽  
Wait List ◽  
Tai Chi Chuan

Purpose: To investigate the effect of Tai Chi Chuan (TCC) to improve immune system and decrease pro-metastasis markers in early post-treatment breast cancer survivors. Methods: 130 post-treatment breast cancer survivors were recruited and randomized 1:1 into TCC group and wait-list (control) group. The TCC group practiced for a 60-minutes session once per week, for a total of 52 weeks. 115 forms of Yang-style TCC were taught by a Tai Chi master. Blood samples were taken from each subject and complete blood count was performed. The expressions of NKG2D protein, P-selectin, and vascular endothelial growth factor (VEGF) in plasma were measured. Lymphocyte activity was measured by cell proliferation reagent and ATP assay. Images of lymphocyte colony formation were taken with an inverted microscope. Results: At 52 weeks, TCC group demonstrated a significantly higher WBC (p=0.001) , a significantly higher NKG2D value (p=0.001) and a significantly lower VEGF value (p=0.005) when compared to the wait-list group. However, there was a small, non-significant change for P-selectin values between the breast cancer survivor groups. After 72h incubation, TCC group had a significant increase in lymphocyte proliferation (p=0.001) and greater area of lymphocyte clusters or colonies (p=0.001). Conclusion: The practice of TCC could stimulate tumor immunosurveillance via NKG2D and activate the immune response. VEGF, a marker playing an important role in breast cancer and its metastases, was also reduced in those who practiced TCC. As an alternative for conventional exercise, post-treatment breast cancer survivors may select TCC in their rehabilitation program.

Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial

2000 ◽  
Vol 18 (5) ◽  
pp. 1068-1068 ◽  
Author(s):  
Susan K. Quella ◽  
Charles L. Loprinzi ◽  
Debra L. Barton ◽  
James A. Knost ◽  
Jeff A. Sloan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Hot Flashes ◽  
Clinical Problem ◽  
Baseline Period ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Hormonal Therapies ◽  
Blind Manner

PURPOSE: Hot flashes represent a significant clinical problem for some breast cancer survivors. Safe, effective treatment is needed for this prominent clinical problem. Although it has been shown that estrogen or progesterone replacement therapy can alleviate this problem, there are continued safety concerns regarding the use of hormonal therapies in these women. Based on anecdotal information, we hypothesized that soy-derived phytoestrogens, weak estrogen-like substances in the soybean that demonstrate estrogen agonist and/or antagonist effects when they bind to estrogen receptors, could alleviate hot flashes. This current trial was designed to investigate this hypothesis. PATIENTS AND METHODS: This double-blind clinical trial involved breast cancer survivors with substantial hot flashes. After randomization, patients underwent a 1-week baseline period with no therapy. This was followed by 4 weeks of either soy tablets or placebo. The patients then crossed over to the opposite arm in a double-blind manner for the last 4 weeks. Patients completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effects. RESULTS: Of the 177 women who were randomized and started the study substance, 155 (88%) provided useable data over the first 5 weeks; 149 provided usable data over the entire 9 weeks. There was no suggestion that the soy product was more effective in reducing hot flashes than the placebo. At study completion, patients preferred the soy product 33% of the time, the placebo 37% of the time, and neither substance 31% of the time. No toxicity was observed. CONCLUSION: The soy product did not alleviate hot flashes in breast cancer survivors.

scholarly journals The association between nocturnal hot flashes and sleep in breast cancer survivors

2004 ◽  
Vol 27 (6) ◽  
pp. 513-522 ◽  
Author(s):  
Josée Savard ◽  
Judith R Davidson ◽  
Hans Ivers ◽  
Catherine Quesnel ◽  
Dominique Rioux ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Hot Flashes

scholarly journals 3367 A Mouse Model of APOE Genotype in Chemotherapy Related Cognitive Impairment

2019 ◽  
Vol 3 (s1) ◽  
pp. 1-1
Author(s):  
Tamar Demby ◽  
G. William Rebeck ◽  
Christopher Albanese ◽  
Olga C. Rodriguez ◽  
Yichien Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Cognitive Impairment ◽  
Cancer Survivors ◽  
Open Field ◽  
Breast Cancer Survivors ◽  
Apoe Genotype ◽  
Post Treatment ◽  
Barnes Maze ◽  
Doxorubicin Treatment

OBJECTIVES/SPECIFIC AIMS: Chemotherapy-related cognitive impairment (CRCI) affects 15-35% of breast cancer survivors and constitutes a significant challenge for survivor quality of life. Among older breast cancer survivors who received chemotherapy treatment, carriers of at least one ɛ4 allele of the APOE gene, which encodes apolipoprotein E, are at higher risk for developing CRCI than non-carriers. APOE4 is well characterized as the strongest genetic risk factor for Alzheimer’s disease, but how it contributes to CRCI is not yet understood, and no animal models of APOE genotype and CRCI have yet been established. To better understand how APOE4 acts as a risk factor for CRCI, we used APOE targeted replacement (TR) mice to develop a model of its effects on cognition following treatment with doxorubicin, a chemotherapy drug commonly used in breast cancer treatment. METHODS/STUDY POPULATION: Twelve-to-thirteen month old APOE3 and APOE4 targeted replacement mice expressing human APOE3 or human APOE4 under control of the endogenous murine promoter were treated with 10 mg/kg doxorubicin or equivolume saline given via two IP injections spaced one week apart. One week post-treatment, mice were tested using Open Field and Elevated Zero apparatuses to assess baseline locomotive activity and anxiety and exploratory behaviors. Five weeks post-treatment, mice were assessed using the Barnes Maze over four days of training trials and one 72 hour memory probe. RESULTS/ANTICIPATED RESULTS: We found no differences in Open Field and Elevated Zero behavior, indicating limited influence of doxorubicin treatment on locomotive and anxiety behaviors in both genotypes. During Barnes Maze training, APOE4 mice treated with doxorubicin showed increased latency compared to untreated APOE4 mice as well as treated and untreated APOE3 mice, indicating deficiencies in spatial learning. In APOE3 mice, no differences in performance were seen between doxorubicin-treated and untreated mice (n = 15-16/group, p <.0001). DISCUSSION/SIGNIFICANCE OF IMPACT: These results indicate that APOE4 targeted replacement mice have specific cognitive vulnerabilities to doxorubicin treatment that can be reliably detected using the Barnes Maze assessment. Future directions include experiments to determine how other chemotherapy drugs or drug combinations impact cognition of APOE4 mice. Ultimately this model may be used to assess preventive measures or therapies for CRCI in the vulnerable APOE4 carrier population with the ability to validate cognitive impacts of these interventions.

Sign in / Sign up

Export Citation Format

Share Document